
News|Articles|September 15, 2026
Updated ASTRO Pancreatic Guidelines: Key Takeaways for Oncology Nurses
Author(s)Alex Biese
Fact checked by: By ONN Staff
ASTRO updated its pancreatic cancer radiation guideline. Dr Michael Chuong shares direct takeaways on nursing roles in multidisciplinary care.
Advertisement
Advertisement
Epidemiologic models project that pancreatic cancer will become the second leading cause of cancer-related mortality in the United States by 2030. In 2026, an estimated 67,500 US adults will receive a diagnosis of pancreatic cancer, with 52,700 deaths and a 5-year survival rate of 13% across all stages. Because fewer than 20% of patients present with surgically resectable disease at initial diagnosis, multidisciplinary management integrating systemic chemotherapy, radiation therapy, and surgical intervention is essential to optimize patient outcomes.
Related to this article

Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.

Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.

FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.

In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.
Advertisement
Advertisement

